SCIENTIFIC BITES®

Cancer research e-learning platform



Futuras terapias para el cáncer de mama HER2+ y HER3+

Cristina Saura: Hospital Universitari de la Vall d'Hebron/VHIO (Barcelona) Santiago Escrivá de Romaní: Hospital Universitari de la Vall d'Hebron/VHIO (Barcelona)



✓ HER2:

Current standard treatment landscape in HER2+ mBC Third line options and beyond:

> -Guidelines recommendations: -Recent efficacy and safety results in the post


> > T-DM1 setting Margetuximab – SOPHIA Neratinib – NALA DS8201 – DESTINY-Breast01 Tucatinib – HER2CLIMB




HER3:

Signaling and targeted therapy in BC


È







Stratification factors: World region, number of prior chemo regimens for MBC or unresectable LABC, presence of visceral disease Primary endpoints: PFS by independent review, OS, and safety

PFS ANALYSIS










Stratification factors: World region, number of prior regimens for advanced BC,d presence of visceral disease Co-primary endpoints: PFS by investigator and OS

Key secondary endpoints: ORR by investigator and safety





There is insufficient evidence to recommend a specific regimen and in general, it is at the physician discretion what is prescribed taking into account patient's preferences and adverse events of each regimen.



* Include in clinical trials when available


© 2018 ESMO. All rights reserved. esmo.org/Guidelines/ Breast-Cancer/4th-ESO-ESMO-International-Consensus-Guidelines-for-Advanced-Breast-Cancer-ABC-4



Veratinib – NALA

- DS8201 DESTINY-Breast01
- Tucatinib HER2CLIMB





Margetuximab^{1,2}

Fab:




- Same specificity and affinity
- Similarly disrupts signaling

Fc engineering:

- ↓ Affinity for inhibitory FcγRIIB (CD32B)

Margetuximab Binding to FcyR Variants:

Receptor Type	Receptor	Allelic Variant	Relative Fc Binding	Affinity Fold-Change
	CD16A	158F	Lower	6.6x ↑
Activating	CDIGA	158V	Higher	4.7x 个
	60224	131R	Lower	6.1x ↓
	CD32A	131H	Higher	\leftrightarrow
Inhibitory	CD32B	232I/T	Equivalent	8.4x ↓




ITT Population: Baseline Characteristics

		Margetuximab + Chemotherapy (n=266)	Trastuzumab + Chemotherapy (n=270)
	Median age	55	56
	Female sex	266 (100%)	267 (98.9%)
Demographics	Europe	152 (57%)	138 (51%)
	North America	85 (32%)	102 (38%)
	Other region	29 (11%)	30 (11%)
	ECOG PS 0	149 (56%)	151 (60%)
	ECOG PS 1	117 (44%)	109 (40%)
	Metastatic	260 (98%)	254 (98%)
	Locally advanced, unresectable	6 (2%)	6 (2%)
Disease Characteristics	Measurable disease by CBA	262 (99%)	262 (97%)
	s2 metastatic sites	138 (52%)	144 (53%)
	>2 metastatic sites	128 (48%)	125 (47%)
	Hormone receptor positive	164 (62%)	170 (63%)
	Hormone receptor negative	102 (38%)	98 (35%)
	Capecitabine	71 (27%)	72 (27%)
Backbone chemotherapy	Eribulin	66 (25%)	70 (26%)
backbone chemotherapy	Gemcitabine	33 (12%)	33 (12%)
	Vinorelbine	96 (36%)	95 (35%)


ITT Population: Prior Cancer Therapy

	Margetuximab + Chemotherapy (n=266)	Trastuzumab + Chemotherapy (n=270)
Settings of prior therapy		
Adjuvant and/or neoadjuvant	158 (59%)	145 (54%)
Metastatic only	108 (41%)	125 (46%)
Prior metastatic lines of therapy		
≤2	175 (66%)	180 (67%)
>2	91 (34%)	90 (33%)
Prior anti-HER2 therapy		
Trastuzumab	266 (100%)	270 (100%)
Pertuzumab	266 (100%)	269 (100%)
T-DM1	242 (91%)	247 (92%)
Lapatinib	41 (15%)	39 (14%)
Other HER2	6 (2%)	6 (2%)
Prior chemotherapy		
Taxane	252 (95%)	249 (92%)
Anthracycline	118 (44%)	110 (41%)
Platinum	34 (13%)	40 (15%)
Prior endocrine therapy	126 (47%)	133 (49%)




PFS analysis was triggered by last randomization on October 10, 2018, after 265 PFS events occurred

ITT population: N=536. Cl=confidence interval.



Rugo H et al, ASCO 2019

ITT Population: Interim OS Analyses (n=536)



Second Interim OS Analysis (Sep-2019 Cutoff)^b

*OS analysis performed as of October 10, 2018 data cutoff, after 158 (41%) of 385 events needed for final OS analysis had occurred. POS analysis performed as of September 10, 2019 data cutoff, after 270 (70%) of 385 events needed for final OS analysis had occurred.

This presentation is the intellectual property of the author/presenter. Contact her at Hope.Rugo@ucsf.edu for permission to reprint and/or distribute.

			etuximab + erapy (n=264)	Trastuzumab + Chemotherapy (n=265)	
M	ost common AEs, n (%)	All Grade	* Grade ≥3 ⁺	All Grade*	Grade ≥3 ⁺
Fa	tigue	103 (39.0) 12 (4.5)	92 (34.7)	7 (2.6)
N	ausea	81 (30.7	3 (1.1)	84 (31.7)	1 (0.4)
N	eutropenia	73 (27.7	51 (19.3)	51 (19.2)	30 (11.3)
Di	arrhea	59 (22.3	6 (2.3)	62 (23.4)	5 (1.9)

File under review by FDA

Febrile neutropenia	8 (3.0)	8 (3.0)	12 (4.5)	12 (4.5)
AEs of special interest, n (%)	All Grade	Grade ≥3	All Grade	Grade ≥3
Infusion-related reaction (IRR)*	34 (12.9)	4 (1.5)	10 (3.8)	0
Left ventricular dysfunction	6 (2.3)	3 (1.1)	7 (2.6)	1 (0.4)
Discontinuation due to IRRs, n (%)	3 (1.1)	2 (0.8)	0	0

Safety Population: N=529.

*Incidence ≥20% in either treatment group.

[†]Incidence ≥5% in either treatment group.


*All patients received prior trastuzumab. In pivotal trials of trastuzumab, IRRs occurred in 21% to 40% of patients (US package insert).

٠

٠

٠

⊨Ì




Inclusion criteria

- Metastatic breast cancer (MBC)
- Centrally confirmed HER2+ disease
- ≥2 lines of HER2-directed therapy for MBC
- Asymptomatic and stable brain metastases permitted

Stratification variables

- Number of prior HER2 therapies for MBC
- Disease location
- HR status
- Geographic location




Endpoints


- Co-primary: PFS (centrally confirmed) and OS
- Secondary: PFS (local), ORR, DoR, CBR, intervention for CNS metastases, safety, health outcomes

Loperamide 4 mg with first dose of neratinib, followed by 2 mg every 4 h for first 3 d, then loperamide 2 mg every 6-8 h until end of Cycle 1. Thereafter as needed

Centrally confirmed PFS (co-primary endpoint)



OS (co-primary endpoint)



	Neratinib + Capecitabine (n=307)	Lapatinib + Capecitabine (n=314)
Age <65 years, n (%)	244 (79)	248 (79)
Geographic region, n (%)		
Europe	121 (39)	123 (39)
North America	59 (19)	65 (21)
Rest of world	127 (41)	126 (40)
HR+ (ER+ and/or PR+), n (%)	181 (59)	186 (59)
Disease location at enrollment, n (%)		
Non-visceral only	60 (20)	61 (19)
Visceral	247 (80)	253 (81)
De novo metastatic disease, n (%)	139 (45)	136 (43)
No. of prior HER2 targeted therapies for MBC, n (%)		
2	215 (70)	215 (68)
≥3	92 (30)	99 (32)
Prior HER2 therapies for MBC, n (%)		
Trastuzumab only	124 (40)	113 (36)
Trastuzumab + pertuzumab	24 (8)	23 (7)
Trastuzumab + T-DM1	58 (19)	64 (20)
Trastuzumab + pertuzumab + T-DM1	101 (33)	114 (36)


PRESENTED AT: 2019 ASCO ANNUAL MEETING MASCO19 Interior the presented for eacher.

PRESENTED BY: Adam Brufsky


7



Centrally confirmed PFS (co-primary endpoint)




NALA TRIAL




OS (co-primary endpoint)

E



Saura et al, ASCO 2019



Saura et al, ASCO 2019


Most frequent grade 3/4 adverse events

	Neratinib + Cap	ecitabine (n=303)	Lapatinib + Cape	Lapatinib + Capecitabine (n=311)		
	All grade	Grade 3/4	All grade	Grade 3/4		
Treatment-emergent AE, %	100	61	99	60		
Diarrhea	83	24*	66	13*		
Hand-foot syndrome	46	10	56	11		
Hypokalemia	12	5	14	6		
Nausea	53	4	42	3		
Vomiting	46	4	31	2		
Fatigue	34	3	31	3		
Neutropenia	7	3	5	2		
Asthenia	12	3	12	2		
Decreased appetite	35	3	22	2	l adverse e	
Dehydration	6	2	6	2	r adverse e	


FDA approved. EMA file in Q3 2020

	Neratinib + Capecitabine (n=303)	Lapatinib + Capecitabine (n=311)
Maximum toxicity, n (%)		
Grade 1	91 (30)	111 (36)
Grade 2	87 (29)	56 (18)
Grade 3	74 (24)	39 (13)
Time to first onset of diarrhea, days		
Grade 2 or 3	9	18
Grade 3	11	38
Median cumulative duration per patient, days		
Grade 2 or 3	7	9
Grade 3	4	4
Treatment discontinuation due to diarr	hea: N+C: 2.6%	L+C: 2.3%

AND ALL ADDRESS AND AND ALL ADDRESS AND AD



1. Nakada T, et al. Chem Pharm Bull (Tokyo). 2019;67(3):173-185. 2. Ogitani Y, et al. Clin Cancer Res. 2016;22(20):5097-5108. 3. Trail PA, et al. Pharmacol Ther. 2018;181:126-142. 4. Ogitani Y, et al. Cancer Sci. 2016;107(7):1039-1046.



Primary: confirmed ORR by independent central imaging facility review per RECIST v1.1

 Secondary: investigator-assessed ORR, DCR, DOR, CBR, PFS, OS, PK and safety

Data Cutoff: August 1, 2019

- 79 patients (42.9%) are ongoing
- 105 patients (57.1%) discontinued, primarily for progressive disease (28.8%)

Patient Baseline Characteristics

	Patients T-DXd 5.4 mg/kg (N=184) ^a
Age, median (range), years	55.0 (28-96)
Female, %	100
Region, % Asia / North America / Europe	34.2 / 28.8 / 37.0
ECOG performance status 0 / 1 / 2, %	55.4 / 44.0 / 0.5
Hormone receptor positive / negative / unknown, %	52.7 / 45.1 / 2.2
HER2 expression, % ^b IHC 3+ IHC 2+; ISH+ /IHC 1+; ISH+	83.7 15.2 / 1.1
Presence of visceral disease, %	91.8
History of brain metastases, %	13.0


•All 184 patients received ≥1 dose of T-DXd. •HER2 status was centrally assessed on archival tissue according to guidelines of the American Society of Clinical Oncology–College of American Pathologists. ECOG, Eastern Cooperative Oncology Group; IHC, immunohistochemistry; ISH, in situ hybridization. San Antonio Breast Cancer Symposium®, December 10-14, 2019

Patient Baseline Characteristics (cont'd)

Median prior lines of cancer therapy: 6 (range 2-27)


Prior Treatment ^a	Patients, % T-DXd 5.4 mg/kg (N=184)
Trastuzumab	100
T-DM1	100
Pertuzumab	65.8
Other anti-HER2 therapies	54.3
Hormone therapy	48.9
Other systemic therapy	99.5

"Therapies for locally advanced or metastatic breast cancer, including hormone therapy.



The line at 20% indicates progressive disease; the line at -30% indicates partial response. a Includes all patients who received T-DXd 5.4 mg/kg (intent-to-treat analysis; N=184).

Krop I al, SABCS 2019 & NEJM 2019



Patients who received T-DXd 5.4 mg/kg. Cl, confidence interval; NE, not estimable.

Krop I al, SABCS 2019 & NEJM 2019

Overall Safety Summary (>15%)

Adverse Events	Any Grade	Grade 3	Grade 4
	,	umber of patients (percent)	
Any adverse eventý	183 (99.5)	89 (48.4)	7 (3.8)
Nausea	143 (77.7)	14 (7.6)	0
Fatigue	91 (49.5)	11 (6.0)	0
Alopecia	89 (48.4)	1 (0.5)	0
Vomiting	84 (45.7)	8 (4.3)	0
Constipation	66 (35.9)	1 (0.5)	0
Decreased neutrophil count‡	64 (34.8)	36 (19.6)	2 (1.1)
Decreased appetite	57 (31.0)	3 (1.6)	0
Anemia§	55 (29.9)	15 (8.2)	1 (0.5)
Diamhea	54 (29.3)	5 (2.7)	0
Decreased white-cell count¶	39 (21.2)	11 (6.0)	1 (0.5)
Decreased platelet count	39 (21.2)	7 (3.8)	1 (0.5)
Headache	36 (19.6)	0	0
Cough	35 (19.0)	0	0
Abdominal pain**	31 (16.8)	2 (1.1)	0
Decreased lymphocyte count††	26 (14.1)	11 (6.0)	1 (0.5)
Adverse events of special interest			
Interstitial lung disease‡‡	25 (13.6)	1 (0.5)	0
Prolonged QT interval	9 (4.9)	2 (1.1)	0
Infusion-related reaction	4 (2.2)	0	0
Decreased left ventricular ejection fraction	3 (1.6)	1 (0.5)¶¶	0

11 The presence of interstitial lung disease was determined by an independent adjudication committee, since the condition has been associated with trastuzumab deruxtecan. Four patients who had grade 5 events are included in the category of any grade.

	F	Patients w	ho receive	d T-DXd 5.	4 mg/kg (N	=184)	
Preferred Term, n (%)							
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Tota	

FDA approved. EMA file in Q3 2020

Drug related; ILD was determined by the Independent ILD Adjudication Committee based on 44 preferred terms.


Median time from the first infusion of T-DXd to onset of ILD was 27.6 weeks (range, 6-76 weeks)

ILD, interstitial lung disease.

Mechanism of Action

Orally bioavailable, potent HER2 selective TKI

HER2 IC50 8 nM > EGFR IC50 > 10,000 nM: Decreased potential for EGFR-related toxicities




San Antonio Breast Cancer Symposium®, December 10-14, 2019

HER2CLIMB Trial Design

Key Eligibility Criteria

- HER2+ metastatic breast cancer
- Prior treatment with trastuzumab, pertuzumab, and T-DM1
- ECOG performance status 0 or 1
- · Brain MRI at baseline
 - Previously treated stable brain metastases
 - Untreated brain metastases not needing immediate local therapy
 - Previously treated progressing brain metastases not needing immediate local therapy
 - No evidence of brain metastases

*Stratification factors: presence of brain metastases (yes/no), ECOG status (0 or 1), and region (US or Canada or rest of world)




This presentation is the intellectual property of the author/presenter. Contact them at murthy1@mdanderson.org for permission to reprint and/or distribute.

		Total Population, N=612	
Characteristic, n (%)		TUC+Tras+Cape n=410	Pbo+Tras+Cape n=202
Female		407 (99)	200 (99)
Age (years), median (range)		55.0 (22, 80)	54.0 (25, 82)
ECOG performance status	0	204 (50)	94 (47)
	1	206 (50)	108 (54)
Stage IV at initial diagnosis		143 (35)	77 (39)
Hormone receptor status	ER and/or PR-positive	243 (60)	127 (63)
	ER and PR-negative	161 (40)	75 (37)
Prior lines of therapy, median (range)	Overall	4.0 (2, 14)	4.0 (2,17)
	Metastatic setting	3.0 (1, 14)	3.0 (1, 13)
Presence/history of brain metastases		198 (48)	93 (46)
Treated, stable		118 (59.6)	55 (59.1)
Untreated		44 (22.2)	22 (23.7)
Treated, progressing		36 (18.2)	16 (17.2)

Presence or history of brain metastases no. (%)	148 (46.2)	71 (44.4)	198 (48.3)	93 (46.0)
Location of other metastases - no. (%)			,	()
Lung	160 (50.0)	82 (51.2)	200 (48.8)	100 (49.5)
Liver	108 (33.8)	64 (40.0)	137 (33.4)	78 (38.6)
Bone	178 (55.6)	85 (53.1)	223 (54.4)	111 (55.0)
Previous lines of therapy, median no. (range)	4 (2-14)	4 (2-17)	4 (2-14)	4 (2-17)
Previous lines of therapy for metastatic cancer, median no. (range)	3 (1–14)	3 (1–13)	3 (1–14)	3 (1–13)
Previous therapies — no. (%)				
Trastuzumab	320 (100)	160 (100)	410 (100)	202 (100)
Pertuzumab	320 (100)	159 (99.4)	409 (99.8)	201 (99.5)
Trastuzumab emtansine	320 (100)	160 (100)	410 (100)	202 (100)
Lapatinib	22 (6.9)	10 (6.2)	24 (5.9)	10 (5.0)


Primary Endpoint: PFS



Projected PFS rates				
	TUC/TRAS/CPC	PLAC/TRAS/CPC		
1 year (95% Cl)	33%	12%		


46% reduction in risk of disease progression

Secondary Endpoint:OS



	2 40/ made ation		
	TUC/TRAS/CPC	PLAC/TRAS/CPC	34% reduction
2 year (95% Cl)	45%	27%	in risk of death


R.K. Murthy et al, SABCS 2019 & NEJM 2019




Projected PFS rates BM					
TUC/TRAS/CPC PLAC/TRAS/CPC					
1 year (95% Cl)	25%	0%			

52% reduction in risk of disease progression

Secondary Endpoint: ORR *







✓ HER2:

Current standard treatment landscape in HER2+ mBC Third line options and beyond:

-Guidelines recommendations:

-Recent efficacy and safety results in the post T-DM1 setting

Margetuximab – SOPHIA Neratinib – NALA DS8201 – DESTINY-Breast01 Tucatinib – HER2CLIMB



HER3:

Signaling and targeted therapy in BC

Abs	Target	Most advanced clinical phase	Clinicaltrials.gov identifier	Current Results on clinicaltrials.gov	Sponsor
mAbs:					
U3–1287/Patritumab	HER3	Phase III	NCT02134015	Terminated (Pre-defined criteria Not reached)	Daiichi Sankyo
MM-121/Seribantumab	HER3	Phase II	NCT00994123	MM-121+ erlotinib ineffective to prolong PFS in EGFR WT NSCLC	Merrimack Pharmaceuticals
RG7116/Lumretuzumab	HER3	Phase I	NCT01482377	No results posted	Roche
LJM716/Elgemtumab	HER3	Phase I/II	NCT01822613	No results posted	Novartis
U3-1402	HER3	Phase I/II	NCT02980341	Ongoing	Daiichi Sankyo
AV-203	HER3	Phase I	NCT01603979	No results posted	Aveo Oncologyo
KTN3379/CDX-3379	HER3	Phase I	NCT02014909	No results posted	Celldex Therapeutics
GSK2849330	HER3	Phase I	NCT01966445	Results submitted, But not posted	GlaxoSmithKline
Bispecific Abs:					
MM-111	HER2/HER3	Phase II	NCT01774851	Terminated (Lack of efficacy)	Merrimack Pharmaceuticals
MCLA-128	HER2/HER3	Phase II	NCT03321981	Ongoing	Merus NV
MM-141/Istiratumab	HER3/IGF-1R	Phase II	NCT02399137	No results posted	Merrimack Pharmaceuticals
MEHD7945A/Duligotumab	HER3/EGFR	Phase II	NCT01652482	No results posted	Genentech


Table 1 Mono- and bi-specific anti-HER3 Abs under clinical studies in cancer patients

HER2	th:	ailing 2-4 prior nerapies g T-DM1)	Age (years), m ECOG PS (0/1) Prior therapies N therapies (median [rang N anti-HER2 Prior pertuz
Doublet MCLA-128 + trastuzumab		Triplet MCLA-128 + trastuzumab + vinorelbine	Prior T-DM1, N metastatic s Lymph node Bone Lung Liver Breast Brain

	N=39
Age (years), median [range]	57 [29-84]
ECOG PS (0/1), N (%)	21 (54%) / 18 (46%
Prior therapies	
N therapies (chemotherapy, anti-HER2, hormonal), median [range]	5 [2-8]
N anti-HER2 lines (metastatic setting), median [range]	3 [1-5]
Prior pertuzumab, N (%)	39 (100%)
Prior T-DM1, N (%)	39 (100%)
N metastatic sites*, median [range]	3 [1-5]
Lymph nodes	22 (56%)
Bone	21 (54%)
Lung	20 (51%)
Liver	13 (33%)
Breast	12 (31%)
Brain	8 (21%)

Table 3. CBR, ORR, and BOR, Investigator assessed (RECIST v1.1)

	N=37
Clinical benefit rate at 24 weeks, N (%) [90%CI]	13 (35.1%) [22.2-50.0]
Overall response rate, N (%) [90%CI]	7 (18.9%) [9.2-32.6]
Best overall response (confirmed)	
Complete response	1 (2.7%)
Partial response	6 (16.2%)
Stable disease	22 (59.5%)
Disease progression	8 (21.6%)




Phase 2 RP2D expansion (enrolled)	mBC (N=10)	Other ¹ (N=9)	Total (N=19)
Age (years), Median (Min;Max)	52 (37;70)	57 (33;74)	54 (33;74)
Gender (male), N (%)	0	6 (67%)	6 (32%)
ECOG P5 (0/1), N	2/8	1/8	3/16
N Metastatic Sites, Median (Min;Max)	3 (1;3)	2 (1;4)	2.5 (1;4)
N Prior Therapies, Median (Min;Max)	6 (4;18)	3 (2;8)	5.5 (2;18)
N Prior HER Therapies, Median (Min;Max)	3 (3;4)	1 (0;2)	3 (0;4)

closed prematurely)

Patient ID	Metastatic sites	N prior lines	N HER2 therapies	Dose (mg)	N cycles	Best response	Response duration (weeks) ¹	
#1	Bone, lung	4	4	750	14	PR	34.4+	
#2	Bone, lymph nodes	6	3	750	12	SD	37.0	
#3	Skin, lymph nodes	5	3	750	11	SD	34.0	
#4	Bone, brain	5	3	750	8	SD	23.3+	
#5	Lung	6	5	480	7	SD	21.4	
#6	Bone, skin	8	3	750	5	SD.	14.9	
#7	Brain, liver, peritoneum	6	2	480	4	SD	12.0	
#8	Skin	18	4	750	4	SD	11.7	
#9	Bone, lymph nodes, skin	5	3	750	2	PD	-	
#10	Lung, lymph nodes, skin	8	2	750	2	PD		
#11	Pleura, lymph nodes, skin	5	3	750	2	PD	-	

Population

- Metastatic or locally advanced breast cancer
- Hormone receptor positive & low-HER2 expression (IHC 1+ or IHC 2+ with no FISH amplification)
- Up to 3 lines of endocrine therapy (metastatic setting)
- Progression on a CDK 4/6 inhibitor
- ≤2 prior chemotherapy regimens for advanced/metastatic disease
- Measurable disease (RECIST v1.1); for bone only disease, lytic only or mixed lesions were accepted




	N=50
Age (years), median [range]	56 [27-82]
ECOG PS (0/1), N (%)	35 (70%) / 15 (35%)
ER-positive, N (%)	50 (100%)
HER2 IHC 1+ / IHC 2+, N (%)	26 (52%) / 24 (48%)
Prior therapies	
N hormone therapy lines, median [range]	2 [1-5]
N chemotherapy lines (all settings), median [range]	1 [1-3]
Prior CDK4/6 inhibitor, N (%)	50 (100%)
N metastatic sites*, median [range]	3 [1-6]
Bone	37 (74%)
Liver	33 (66%)
Lymph nodes	27 (54%)
Lung	14 (28%)

* Sites present in >20% of the cohort.


Table 3. CBR, ORR, and BOR, Investigator assessed (RECIST v1.1)

	N=48			
Clinical benefit rate at 24 weeks, N (%) [90%Cl]	8 (16.7%) [8.6-28.1]			
Overall response rate, N (%) [90%CI]	1 (2.1%)[0.1-9.5]			
Best overall response (confirmed)				
Complete response	0			
Partial response	1 (2.1%)			
Stable disease	20 (41.7%)			
Disease progression	26 (54.2%)			
Unknown*	1 (2.1%)			
* 1st assessment was SD at week 5; 2nd assessment was PD at week 15				

Phase 1/2, HER3 positive tumors (IHC +2,+3), mediana de 5 (1-12) lineas de tratamiento para CM metastasico




	Dose Escalation + Dose Finding					
Efficacy Measures	4.8 mg/kg (N = 15)	6.4 mg/kg (N = 15)	All dose levels (N = 42)			
ORR, n/N (%)	6/15 (40.0)	9/15 (60.0)	18/42 (42.9)			
DoR, median (range), months	NR (2.8, 9.8+)	NR (2.9+, 9.8+)	NR (2.8, 13.8+)			
TTR, median (95% CI), months	2.1 (1.3, 4.1)	2.7 (1.4, 2.8)	2.6 (1.4, 2.8)			
DCR, n/N (%)	13/15 (86.7)	15/15 (100.0)	38/42 (90.5)			
PFS, median (range), months ^a	8.0 (1.2, 12.3+)	NR (5.0, 11.1+)	8.3 (1.2, 16.8+)			



HER Kinase inhibition in patients with HER2- and HER3-mutant cancers

Extended Data



Outcome	HER2										HER3
	Breast (n=25)	Lung (n=26)	Bladder (n=16)	Colorectal (n=12)	Biliary tract (n=9)	Cervical (n=5)	Endometrial (n=7)	Gastroesophageal (n=5)	Ovarian (n=4)	NOS (n=16)	NOS (n=16)
ORR at week 8, n (%) [95% CI]	8 (32.0) [14.9–53.5]	1 (3.8) [0.1–19.6]	0 (0.0) [0.0–20.6]	0 (0.0) [0.0-26.5]	2 (22.2) [2.8-60.0]	1 (20.0) [0.5-71.6]	0 (0.0) [0.0-41.0]	0 (0.0) [0.0-52.2]	0 (0.0) [0.0-60.2]	1 (6.3) [0.2–30.2]	0 (0.0) [0.0–20.6]
ORR, n (%) [95% CI]	6 (24.0) [9.4-45.1]	1 (3.8) [0.1–19.6]	0 (0.0) [0.0–20.6]	0 (0.0) [0.0–26.5]	0 (0.0) [0.0-33.6]	1 (20.0) [0.5-71.6]	0 (0.0) [0.0-41.0]	0 (0.0) [0.0-52.2]	0 (0.0) [0.0-60.2]	0 (0.0) [0.0–20.6]	0 (0.0) [0.0–20.6]
Clinical benefit rate, n (%) [95% Cl]	10 (40.0) [21.1-61.3]	11 (42.3) [23.4-63.1]	3 (18.8) [4.0–45.6]	1 (83) [0.2-38.5]	3 (33.3) [7.5-70.1]	3 (60.0) [14.7-94.7]	2 (28.6) [3.7–71.0]	1 (20.0) [0.5–71.6]	0 (0.0) [0.0-60.2]	3 (18.8) [4.0-45.6]	2 (12.5) [1.6-38.3]
Median PFS, months	3.5	5.5	1.8	1.8	2.8	20.1	2.6	1.7	2.1	1.9	1.7

Conclusions

Patients with HER2+ MBC have substantially improved outcomes with the introduction of the double blockage with trastuzumab and pertuzumab in the first line setting and T-DM1 beyond first line progression.

Despite these important therapeutic advances, most patients will eventually relapse and get somehow resistant. Novel therapeutic options with efficacy in third line and beyond showed great benefits to improve patients outcomes

- FDA approval for neratinib, DS-8201 and tucatinib. Margetuximab under review

- Eagerly awaited EMA approval for these drugs: tucatinib under review

In order to decide on the best strategy following progression beyond second line, we may consider:

- Efficacy and toxicity profile of each drug
- Clinical characteristics of patients
- Previous treatments received and responses achieved
- Biomarker analysis from each trial that may identify patients that could benefit differently from each treatment
- Some promising anti HER3+ therapies under development. Stay tuned to this topic as potential new opportunities for a new HER3+ population and anti-HER3 treatments





Gracias! csaura回vhio.net

SCIENTIFIC BITES®

Cancer research e-learning platform

Thank you

